1. А.М. Курильщиков. Методы и объекты метагеномных исследований / А.М. Курильщиков, Н.В. Тикунова, М.Р. Кабилов // Вестник НГУ, Серия: Биология, клиническая медицина. 2012. Том 12 (выпуск 1). C. 191–201.
2. P.J. Turnbaugh. The human microbiome project / P.J. Turnbaugh, R.E. Ley, M. Hamady [et al.] // Nature. 2007. Vol. 449 (7164). P. 804–810. doi: 10.1038 / nature06244.
3. S.P. Yenamandra. Nuclear receptors and their role in Epstein-Barr virus induced B cell transformation. Review / S.P. Yenamandra, G. Klein, E. Kashuba // Experimental Oncology. 2009. Vol. 31 (2). P. 67–73.
4. Т.А. Clayton. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism / T.A. Clayton, D. Baker, J.C. Lindon [et al.] // Proc. Natl. Acad. Sci. USA. 2009. Vol. 106 (34). P. 28–33. doi:10.1073/pnas.0904489106.
5. К. Mima. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis / K. Mima, R. Nishihara, Z.R. Qian [et al.] // Gut. 2016. Vol. 65 (12). P. 1973–1980. doi:10.1136 / gutjnl-2015–310101.
6. J. Repass. Biology RPC. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma / J. Repass, N. Maherali, К. Owen // Elife. 2016. 5. P. 10–12. doi:10.7554/eLife.10012.
7. О.Е. Кузнецов. Вирусассоциированный рак печени / О.Е. Кузнецов, В.М. Цыркунов // Гепатология и гастроэнтерология. 2021. Том 5(1). С. 17–24. doi.org/10.25298/2616–5546–2021–5–1–17–24.
8. A.G. Neto. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma / A.G. Neto, A. Whitaker, Z. Pei // Semin Oncol. 2016. Vol. 43. P. 86–96. doi:10.1053/j.seminoncol.
9. F. Aviles-Jimenez. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer / F. Aviles-Jimenez, F. Vazquez-Jimenez, R. Medrano-Guzman [et al.] // Sci Rep. 2014. Vol. 4:4202. doi:10.1038/srep04202.
10. E.D. Kuugbee. Structural change in microbiota by a probiotic cocktail enhances the gut barrier and reduces cancer via TLR2 signaling in a rat model of colon cancer / E.D. Kuugbee, X. Shang, Y. Gamallat [et al.] // Dig Dis Sci. 2016. Vol. 61 (10). P. 2908–2920. doi:10.1007/s10620–016–4238–7.
11. B. Ou. Survival of colorectal cancer in patients with or without inflammatory bowel disease: a metaanalysis / B. Ou, J. Zhao, S. Guan, A. Lu // Dig Dis Sci. 2016. Vol. 61 (3). P. 881–889. doi:10.1007/s10620–015–3940–1.
12. O.I. Coleman. Role of the microbiota in colorectal cancer: updates on microbial associations and therapeutic implications / O. I. Coleman, T. Nunes // Biores Open Access. 2016. Vol. 5 (1). P. 279–288. doi:10.1089/ biores.2016.0028.
13. W. Borena. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults / W. Borena, S. Strohmaier, A. Lukanova [et al.] // Int. J. Cancer. 2012. Vol.131(1). P. 193–200. doi:10.1002/ijc.26338.
14. P. Ambalam. Probiotics, prebiotics and colorectal cancer prevention / P. Ambalam, M. Raman, R.K. Purama, M. Doble // Best Pract Res Clin Gastroenterol. 2016. Vol. 30 (1). P. 119–131. doi:10.1016/j.bpg.2016.02.009.
